NCT03470922 2025-09-09RELATIVITY-047Bristol-Myers SquibbPhase 2/3 Active not recruiting714 enrolled 17 charts 1 FDA
NCT04695977 2025-09-05CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced MelanomaRegeneron PharmaceuticalsPhase 2/3 Terminated20 enrolled 18 charts
NCT00003816 2021-08-13Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic CancerRoswell Park Cancer InstitutePhase 2/3 Completed361 enrolled 16 charts
NCT03552549 2019-07-24SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)Merck Sharp & Dohme LLCPhase 2/3 Terminated126 enrolled 9 charts
NCT03116698 2019-04-24A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment PeriodDr. Reddy's Laboratories LimitedPhase 2/3 Completed240 enrolled 13 charts
NCT02829775 2017-01-09A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical StudiesHoffmann-La RochePhase 2/3 Completed9 enrolled 7 charts